Media Hub

Oct 2016

Cancer immunotherapy drug potential ‘game changer’

The European Cancer Congress has presented promising results in a study of 350 head and neck cancer patients. In the study, the number of patients surviving for longer whilst taking the drug, nivolumab, exceeded those being treated with chemotherapy. In the trial published in the New England Journal of Medicine, 36% of the patients trialled…

Read More